Immedica Pharma was established in 2018 by Impilo and a management team with previous experience in launching and commercialising orphan drugs across Europe. The business has developed drugs primarily within haematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need, with revenues of €100m and annual growth of more than 50%, according to the press release.
KKR is investing in Immedica through its KKR Health Care Strategic Growth Fund II, a $4bn fund focused on high-growth healthcare companies. KKR has invested approximately $20bn in the healthcare sector since 2004.
Source: Private Equity Wire
Can’t stop reading? Read more
Bain Capital and Cinven explore sale of Stada as private equity interest mounts
Bain Capital and Cinven explore sale of Stada as private equity interest mounts German...
Axcel launches €266m continuation fund to support SuperOffice’s next growth phase
Axcel launches €266m continuation fund to support SuperOffice’s next growth phase Axcel has...
Swander Pace Capital adds Maple Donuts to growing bakery empire
Swander Pace Capital adds Maple Donuts to growing bakery empire Swander Pace Capital has acquired...